• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

    2/25/25 8:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLSA alert in real time by email

    NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. This innovative approach works by reducing microglial activation, a key factor in the persistent brain inflammation associated with long COVID, thereby addressing the debilitating neurological and psychiatric symptoms many patients face.

    Long COVID is a complex and often debilitating complication following COVID-19 infection. It affects millions worldwide, presenting with symptoms such as persistent fatigue, cognitive impairment ("brain fog"), and psychiatric issues like depression. A growing body of evidence highlights that long COVID is linked to sustained brain inflammation and microglial activation, which disrupts normal brain function. PET imaging studies confirm increased microglial activity in individuals suffering from long COVID, underlining the urgent need for targeted therapies.

    Previously, Tiziana conducted a human clinical study in patients with mild to moderate COVID-19 where foralumab was nasally administered once a day for 10 consecutive days. Treatment was well-tolerated and produced significant reduction in lung inflammation as assessed by computerized tomography (CT) scanning. The aim of the human study was to assess safety of intranasal Foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation who were outpatients at the Santa Casa de Misericordia de Santos Hospital in Brazil.

    Tiziana's nasal anti-CD3 platform has previously demonstrated efficacy in reducing microglial activation in models of central nervous system (CNS) diseases, including multiple sclerosis (MS) and Alzheimer's Disease.

    "Long COVID has challenged the medical community with its complexity, but targeting microglial activation through nasal anti-CD3 presents a promising therapeutic avenue," commented Tiziana's CEO, Ivor Elrifi. "A study in secondary progressive multiple sclerosis showed both clinical improvement and decreased microglial activation via TSPO PET imaging, providing a solid foundation for this Long COVID hypothesis. Importantly, nasal anti-CD3 was well tolerated, with no serious adverse events."

    About Foralumab

    Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

    Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development, binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been observed in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]

    About Tiziana Life Sciences

    Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

    For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

    Forward-Looking Statements

    Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors' in Tiziana's Annual Report on Form 20-F for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission.The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

    For further inquiries:

    Tiziana Life Sciences Ltd

    Paul Spencer, Business Development, and Investor Relations

    +44 (0) 207 495 2379

    email: [email protected]

    [1] https://www.pnas.org/doi/10.1073/pnas.2220272120

    [2] https://www.pnas.org/doi/10.1073/pnas.2309221120



    Primary Logo

    Get the next $TLSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

      Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05). NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced promising results from an open-label clinical study evaluat

      5/6/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The University of Massachusetts (UMass) has now joined Brigham and Women's Hospital (BWH), Yale Multiple Sclerosis Center, and Johns Hopkins University (JHU) Autoimmunity Center of Excellence

      4/23/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

      NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Other active clinical sites in the study include Brigham and Women's Hospital (BWH) and MS Center at Yale Medical Center. The randomiz

      4/2/25 8:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Leadership Updates

    Live Leadership Updates

    See more

    $TLSA
    SEC Filings

    See more
    • Tiziana Life Sciences Appoints New Chief Executive Officer

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building in

      8/19/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

      NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious "Giants of MS" award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multipl

      5/30/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

      Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates. Dr. Clementi brings with

      8/23/23 10:30:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/9/25 7:00:19 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 20-F/A filed by Tiziana Life Sciences Ltd.

      20-F/A - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/8/25 5:00:51 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Tiziana Life Sciences Ltd.

      20-F - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/6/25 5:02:01 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Financials

    Live finance-specific insights

    See more
    • Tiziana Life Sciences Announces Date of Annual General Meeting 2022

      NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge

      12/6/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

      NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our

      11/10/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

      NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021  Time:4:15 p.m. Eastern Time  Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)

      9/7/21 2:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zacks Investment Research initiated coverage on Tiziana Life Sciences with a new price target

      Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50

      4/12/21 11:57:17 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tiziana Life Sciences Ltd.

      SC 13G - Tiziana Life Sciences Ltd (0001723069) (Subject)

      5/4/22 4:34:27 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Tiziana Life Sciences plc

      SC 13D - Tiziana Life Sciences Ltd (0001723069) (Subject)

      1/4/22 4:31:31 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Tiziana Life Sciences plc (0001723069) (Subject)

      2/16/21 7:32:16 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care